In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA1c vs. daily glargine at 52 wk
- PMID: 37782932
- DOI: 10.7326/J23-0079
In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA1c vs. daily glargine at 52 wk
Abstract
Rosenstock J, Bain SC, Gowda A, et al; ONWARDS 1 Trial Investigators. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023;389:297-308. 37356066.
Conflict of interest statement
Comment on
-
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.N Engl J Med. 2023 Jul 27;389(4):297-308. doi: 10.1056/NEJMoa2303208. Epub 2023 Jun 24. N Engl J Med. 2023. PMID: 37356066 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous